Phase III Data In Suspected NASH Boost Madrigal’s Profile, But Bigger Data To Come

 
• By Joseph Haas
  
Madrigal office
Madrigal unveils additional data de-risking NASH candidate resmetirom • Source: Madrigal
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D